In a victory for the makers of OxyContin, a federal appeals court on Wednesday overturned a decision that found patents protecting the powerful painkiller were invalid because the company deliberately misled the U.S. Patent Office.

The decision by the U.S. Court of Appeals for the Federal Circuit sends the case back to a federal trial court in New York to determine whether Purdue Pharma’s patents are enforceable.